Table 2.
Odds ratio of VTEs based on prespecified subgroups
| VTEs, Number/total number | ||||||||
|---|---|---|---|---|---|---|---|---|
| Group | Subgroup | Number of trials | Gemcitabine | Non-gemcitabine | I2(%) | Odds ratio (95% CI) | P for odds ratio | P for group difference |
| Overall | 13 | 27/1654 | 19/2169 | 0 | 1.56 (0.86, 2.83) | 0.145 | NA | |
| Tumour type | NSCLC | 8 | 13/1119 | 13/1665 | 0 | 1.27 (0.57–2.82) | 0.554 | 0.895 |
| Pancreas | 2 | 4/82 | 0/59 | 0 | 5.03 (0.59, 42.62) | 0.138 | ||
| MBC | 3 | 10/453 | 6/445 | 0 | 1.66 (0.62, 4.47) | 0.318 | ||
| Phase of trials | Phase II | 5 | 14/273 | 8/299 | 0 | 1.72 (0.72, 4.10) | 0.224 | 0.790 |
| Phase III | 8 | 13/1381 | 11/1870 | 0 | 1.43 (0.63, 3.24) | 0.392 | ||
| Publication year | 2000–2005 | 3 | 7/396 | 5/591 | 0 | 1.91 (0.60, 6.12) | 0.276 | 0.761 |
| 2006–2012 | 10 | 20/1258 | 14/1578 | 0 | 1.45 (0.72, 2.90) | 0.295 | ||
| Ethnics | Asian | 3 | 6/455 | 2/755 | 0 | 3.27 (0.79, 13.48) | 0.101 | 0.553 |
| Non-Asian | 10 | 21/1199 | 17/1414 | 0 | 1.33 (0.69, 2.56) | 0.398 | ||
MBC, metastatic breast cancer; NA, not available; NSCLC, non-small-cell lung cancer.